Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
37 /100
MEDIUM RISK
Score updated Aug 28, 2026

KTTA — Pasithea Therapeutics Corp. Dilution Risk Tracker

Track KTTA dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track KTTA — Get alerts when the score changes →

As of August 28, 2026, Pasithea Therapeutics Corp. (KTTA) has a DilutionWatch DilutionScore of 37/100, rated MEDIUM dilution risk. Pasithea Therapeutics Corp. has a market capitalization of $23.90M, 33.41M shares outstanding, 21 institutional holders tracked. Stored dilution-related fields include 1.22M outstanding warrants.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
0
📊 Float Risk
37
⚠️ Warrant Exposure
15
🔄 Convertible Debt
40

Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
model est. 27%
🔄 Reverse Split model est. 55%
• 50-day avg $0.75 below $1 exchange minimum
🔔 Track KTTA — Get forecast alerts →

Market Data

Market Cap$23.90M
Shares Outstanding33.41M
Float18.68M
Cash$45.66M
DebtN/A
Short InterestN/A

Institutional Holdings

QoQ: ↑ 32.4% shares (2026Q1 vs prior)
21 institutional holders · 17.07M shares
#1 Vivo Capital, LLC 4.20M shares
#2 JANUS HENDERSON GROUP PLC 4.20M shares
#3 Squadron Capital Management LLC 2.10M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest196.6K
Days to Cover1.0
% of Float1.1%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31
8-K 8K EVENT 2026-05-04
3 FORM3 2026-04-17
Full SEC filing analysis available with free account

Recent News

No recent news

Factual KTTA Dilution Snapshot

Pasithea Therapeutics Corp. (KTTA) has a DilutionScore of 37/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track KTTA Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking KTTA — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for KTTA
KTTA FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.